Drug Trial Radar · NCT04175431
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 30, 2020
Primary completion
Jul 1, 2032
Study completion Jul 1, 2037
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Blue Earth Diagnostics
- First posted
- Nov 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Conditions
- Prostate Adenocarcinoma
Interventions
Positron Emission TomographyProcedure
Undergo fluciclovine PET/CT
LymphadenectomyProcedure
Undergo lymphadenectomy
Radiation TherapyRadiation
Undergo radiation therapy
Abiraterone AcetateDrug
Given PO
PrednisoneDrug
Given PO
Computed TomographyProcedure
Undergo fluciclovine PET/CT
AbirateroneDrug
Given PO
PSMA PET ScanProcedure
Undergo PSMA PET scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Undetectable PSA (< 0.2 ng/mL) rateTime frame: At 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania · Recruiting
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.